The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Neuronal TIMP‐1 release accompanies astrocytic MMP‐9 secretion and enhances astrocyte proliferation induced by β‐amyloid 25–35 fragment
Abstract
The neuropathology of Alzheimer's disease (AD) is accompanied by an inflammatory response that includes neurodegeneration and glial reactivity. Tissue remodeling proteins, such as matrix metalloproteinases (MMPs) and their endogenous tissue inhibitors (TIMPs), are inflammatory mediators that might play a dual role in the AD brain. We aimed to investigate the effects of β‐amyloid (Abeta) on the MMP‐9/TIMP‐1 balance and its involvement in Abeta toxicity in neurons and glial cells. Our results demonstrate that the neurotoxic 25–35 Abeta fragment induces the activation of MMP‐9 and the increase of proMMP‐2/9 secretion and promotes the release of TIMP‐1 in a mixed cortical neuroglial culture. The same treatments performed in pure neuronal or astrocytic cultures confirm that astroglial cells are the major source of MMP‐9, whereas increased TIMP‐1 levels have a neuronal origin. Moreover, 25–35 Abeta fragment not only induced a release of these molecules but also caused expressional changes in MMP‐9 and TIMP‐1, correlated with the neurotoxicity process. We also show that TIMP‐1 promoted cell proliferation in a mixed neuroglial culture, and we confirm this effect in primary cultured astrocytes induced by rTIMP‐1 and 25–35 Abeta. Because the proliferative effect caused by Abeta 25–35 was enhanced by the presence of TIMP‐1, we suggest that the astroglial reactivity induced by chronic exposure of the peptide might be mediated in part by TIMP‐1, which is secreted mainly by injured neurons. In conclusion, our data suggest that the Abeta 25–35 fragment stimulates the MMP‐9–TIMP‐1 pathway, promoting gliosis, in a self‐defensive attempt to eliminate amyloid deposition from AD brains. © 2009 Wiley‐Liss, Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
TIMP-1 promotes astrocyte proliferation.
“which in turn promotes astrocyte proliferation (Ogier et al., 2005; Hernandez-Guillamon et al., 2009)”
From Emerging Alternative Proteinases in APP Metabolism and Alzheimer’s Disease Pathogenesis: A Focus on MT1-MMP and MT5-MMP (2019) · cites this paper as Hernandez-Guillamon et al., 2009
Citations
Cites
S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death
Gu, Z., Kaul, M., Yan, B., Kridel, S. J., Cui, J., Strongin, A., Smith, J. W., Liddington, R. C., & Lipton, S. A. (2002) · Science · doi:10.1126/science.1073634 · Cited by 950
Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380 · cited 4×
“Another increasingly relevant family of proteases that has been shown to degrade Abeta in vitro is the matrix metalloproteinases (MMPs), specifically two gelatinases, MMP-2 (Roher et al., 1994) and MMP-9 (Backstrom et al., 1996; Yan et al., 2006).”
BackgroundInfluentialBackstrom, J. R., Lim, G. P., Cullen, M. J., & Tökés, Z. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-07910.1996 · Cited by 331 · cited 3×
“In fact, increased expression of MMP-9 and TIMP-1 has been found around Abeta depositions in post-mortem AD brains (Peress et al., 1995; Backstrom et al., 1996; Asahina et al., 2001).”
BackgroundEckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196 · cited 1×
“The most relevant proteases with such a degrading property include neprilysin (Howell et al., 1995; Iwata et al., 2000), insulin-degrading enzyme (Kurochkin and Goto, 1994; Farris et al., 2003), endothelinconverting enzyme (Eckman et al., 2006), and cathepsin B (Mueller-Steiner et al., 2006).”
Background
Flagged first, then by citations
Research works printed but not linked: 41
- Anthony DC, 1997, Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke, Neuropathol Appl Neurobiol, 5, 406, 10.1111/j.1365-2990.1997.tb01315.x · DOI
- 10.1016/0006-8993(92)90380-R · DOI
- Asahina M, 2001, Expression of matrix metalloproteinase‐9 and urokinase‐type plasminogen activator in Alzheimer's disease brain, Clin Neuropathol, 20, 60
- 10.1111/j.1365-2990.2007.00897.x · DOI
- 10.1016/S0167-4838(99)00279-4 · DOI
- 10.1016/S0304-3940(97)00859-8 · DOI
- 10.1038/sj.bjc.6603378 · DOI
- 10.1046/j.1471-4159.1996.66041641.x · DOI
- 10.1016/S0006-8993(03)02344-8 · DOI · Paper page
- 10.1523/JNEUROSCI.17-20-07736.1997 · DOI
- 10.1073/pnas.0230450100 · DOI
- 10.1523/JNEUROSCI.13-08-03510.1993 · DOI
- 10.1523/JNEUROSCI.1563-05.2005 · DOI
- 10.1016/j.brainres.2006.06.041 · DOI
- 10.1126/science.1072994 · DOI · Paper page
- 10.1016/0014-5793(92)80015-9 · DOI
- 10.1016/0196-9781(95)00021-B · DOI
- 10.1016/S0006-8993(99)01804-1 · DOI
- Iwata N, 2000, Identification of the major Abeta1–42‐degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition, Nat Med, 6, 43, 10.1038/72237 · DOI · Paper page
- 10.1046/j.1460-9568.2003.02876.x · DOI · Paper page
- 10.1111/j.1460-9568.2005.04426.x · DOI
- 10.1046/j.1471-4159.2003.01745.x · DOI
- 10.1016/0014-5793(94)00387-4 · DOI · Paper page
- 10.1016/j.jns.2004.11.041 · DOI
- 10.1016/j.bbrc.2003.11.050 · DOI
- 10.1016/S0022-510X(02)00398-2 · DOI
- 10.1016/S0197-0186(03)00004-4 · DOI · Paper page
- 10.1016/j.neuron.2006.07.027 · DOI
- 10.1016/S0169-328X(02)00132-8 · DOI · Paper page
- 10.1186/1471-2202-6-68 · DOI · Paper page
- 10.1097/00005072-199501000-00002 · DOI · Paper page
- 10.1046/j.1471-4159.1995.64010253.x · DOI · Paper page
- 10.1523/JNEUROSCI.17-11-04223.1997 · DOI · Paper page
- 10.1046/j.0953-816x.2001.01838.x · DOI · Paper page
- 10.1006/bbrc.1994.2872 · DOI
- 10.1161/01.STR.0000223001.06264.af · DOI
- 10.1038/399a023 · DOI · Paper page
- 10.1016/S1044-7431(02)00024-6 · DOI
- 10.1111/j.1471-4159.2005.03102.x · DOI
- 10.1523/JNEUROSCI.2085-06.2006 · DOI · Paper page
- 10.1038/35081571 · DOI
Cited by
Sorted by citations
García-González, L., Pilat, D., Baranger, K., & Rivera, S. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00244 · Cited by 88
Metadata
- Authors
- Hernández‐Guillamon, M., Delgado, P., Ortega, L., Pares, M., Rosell, A., García‐Bonilla, L., Fernández‐Cadenas, I., Borrell‐Pagès, M., Boada, M., & Montaner, J.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2009-02-23
- Volume
- 87
- Issue
- 9
- Pages
- 2115-2125
- ISSN
- 0360-4012
- 1097-4547
- Cited by
- 39
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review